Trial Profile
A Pilot Clinical Trial of Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 25 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 31 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 31 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.